What is Infinity Bio?
Founded in 2023, Infinity Bio has rapidly established itself as a pivotal player in the biotechnology sector through its innovative MIPSA technology. By providing high-fidelity antibody profiling, the company addresses complex challenges in immunology for a diverse clientele, including pharmaceutical giants and academic research institutions. Their business model, which emphasizes precision and scalability, positions them as a key infrastructure partner for organizations seeking to decode the intricacies of the human immune system. The company's focus on delivering actionable insights through advanced diagnostics marks a significant shift in how biomedical research is conducted and accelerated.
How much funding has Infinity Bio raised?
Infinity Bio has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2025): $5M, investors not publicly disclosed
Key Investors in Infinity Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Infinity Bio?
With this major enterprise-level funding, Infinity Bio is well-positioned to expand its operational footprint and enhance its proprietary technology stack. The strategic deployment of this capital will likely focus on increasing laboratory throughput, broadening the application of MIPSA technology across new therapeutic areas, and strengthening partnerships within the global pharmaceutical ecosystem. As the company moves beyond its initial development stage, the focus will shift toward commercializing its service offerings at scale, ensuring that its antibody profiling solutions become a standard component of modern drug discovery and diagnostic workflows. Future growth will be defined by the firm's ability to maintain its scientific rigor while meeting the increasing demand for high-throughput immunological data.
See full Infinity Bio company page
